Skip to main content
padlock icon - secure page this page is secure

Open Access Pigment epithelium-derived factor (PEDF): drug developmental challenges ahead for a budding anti-angiogenic

Download Article:
 Download
(PDF 61.1 kb)
 
One of the most potent anti-angiogenic biological discovered to date, pigment epithelium-derived factor (PEDF) is fast becoming an exciting and promising lead candidate. Recent studies have shown that even shortened versions of the protein can serve as therapeutic agents with similar activity as the parent molecule. The next obvious challenge is to find ways to deliver this molecule in vivo with enhanced pharmacodynamics and reduced toxicity. Several methods to achieve this are proposed.
No References for this article.
No Supplementary Data.
No Article Media
No Metrics

Document Type: Research Article

Affiliations: 1: Departments of Orthopaedics and Surgery, University of Melbourne, St. Vincent’s Hospital, P.O. Box 2900, Fitzroy, Melbourne, 3065, Australia, Email: [email protected] 2: Departments of Orthopaedics and Surgery, University of Melbourne, St. Vincent’s Hospital, Melbourne, Australia 3: Bone and Soft Tissue Sarcoma Service, Peter MacCallum Cancer Institute, Melbourne, Australia

Publication date: January 1, 2008

More about this publication?
  • Pharmazie is a leading journal in the field of pharmaceutical sciences. As a peer-reviewed scientific journal, Pharmazie is regularly indexed in the relevant databases like Web of science, Journal Citation Reports and many others. The journal is open for submissions from the whole spectrum of pharnaceutical sciences including Pharmaceutical Chemistry, Experimental and Clinical Pharmacology, Drug Analysis, Pharmaceutics, Pharmaceutical Biology, Clinical Pharmacy etc.
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more